NYT : Meta in Talks to Lease Computing Power to Anthropic in Potential $10 Billi

Meta in Talks to Lease Computing Power to Anthropic in Potential $10 Billion Deal
A deal would underline how scarce computing power is for artificial intelligence development, and could create a new business for Meta.

Meta is in talks to lease computing power from its artificial intelligence data centers to Anthropic in a deal that could be worth as much as $10 billion over two years, three people with knowledge of the discussions said, a potential step toward a new A.I. business for the social networking company.

Anthropic proposed the deal in June and Meta is considering it, said the people, who were not authorized to discuss confidential conversations. While the specifics were in flux, Anthropic would pay Meta in monthly increments over the two-year period, the people said. The companies would be able to opt out of any agreement early, they added.

Anthropic’s proposal to Meta was about a third of the size of a deal that the A.I. start-up signed with Elon Musk’s SpaceX in May. Under that agreement, Anthropic is paying the rocket company $45 billion over three years — or $1.25 billion a month — for computing power. The deal included similar provisions that let either company exit the agreement early.

Meta’s talks with Anthropic are in their early stages and may not result in a deal, the people with knowledge of the discussions said. Anthropic and Meta declined to comment.

The talks underline how eager leading A.I. companies are to get their hands on more computing power to rapidly develop the technology, as tech giants including Meta, Google and Microsoft shovel hundreds of billions of dollars into building dozens of new data centers all over the world. The construction boom, which has raised spending by tech companies to an extraordinary degree, has stirred concerns on Wall Street about whether such sums can be justified.

For Meta, a deal would be especially significant. It could open a new line of business for the company and potentially alleviate pressure from investors, who have questioned how much Meta has been spending on data centers to develop cutting-edge A.I. models. Mark Zuckerberg, its chief executive, has said his company will spend as much as $145 billion this year, much of it on A.I., which would be more than double the $72 billion it spent last year.

But Meta has faced questions about whether its own A.I. models can compete with those developed by rivals like Anthropic and OpenAI. And the company has acknowledged that it may build more data centers than it needs, relative to the number of customers using its A.I. products. Selling excess computing power to companies like Anthropic could provide Meta with a new revenue stream until demand for its own A.I. services catches up.

On recent calls with investors, Mr. Zuckerberg hinted that selling computing power could be one way for Meta to see some return on its A.I. investments.

“Almost every week there are different companies that come to us from the outside asking us” about computing power “that they could buy from us at some premium to what we’ve bought it at,” Mr. Zuckerberg said on an investor call in May. “We haven’t done that yet because we think we have a use for the compute.”

“But obviously if we get to a point where we feel that we have overbuilt, then that is an option that we have, and that is partially what gives us confidence in investing in building this out,” he said.

A.I. companies have grown more comfortable striking deals with rivals out of necessity because of how scarce computing power has become. Anthropic, which is valued at nearly $1 trillion in the private market and has filed to go public, has seen a surge in demand since the release of its enterprise software product, Claude Code. As a result, it has needed to work with companies that own large amounts of processing power to serve its growing customer base.

Since Meta does not have a business selling its computing power, that has complicated its talks with Anthropic, one of the people with knowledge of the discussions said.

Meta has also struck its own deals to rent computing power from other data center providers, even as it builds it own facilities. That includes a $21 billion deal with CoreWeave, a provider of A.I. computing power, in April and a $27 billion deal with Nebius, another such company, in March.

Since those deals were signed, the price of computing power has skyrocketed because of limited supply and increased demand, said Mandeep Singh, a technology analyst at Bloomberg Intelligence. That has presented Meta with an opportunity to rent out its data centers while still investing in its own A.I. in the long term, he added.

FT : Hotel group Accor hired law firm to investigate conduct of CEO Bazin Report

Hotel group Accor hired law firm to investigate conduct of CEO Bazin
Report found no wrongdoing after probing allegations of impropriety in Accor’s dealings with associates of Bazin

The board of hotel group Accor hired an elite Paris law firm to carry out a probe into the conduct of chief executive Sébastien Bazin, in response to allegations of conflicts of interest and favouritism under his leadership.

The investigation, which concluded in recent weeks, was requested by Bazin after an anonymous document laying out a series of allegations in detail was circulated to board members, according to three people with knowledge of the situation.

The probe examined Accor’s dealings with Paris Society, the hospitality business owned by Bazin’s close associate Laurent de Gourcuff, and allegations of favouritism in the appointment of a woman to a senior position in the group, according to the people.

The woman is in a long-term romantic relationship with Bazin, according to people familiar with the situation. However, the relationship between the two was not mentioned in the allegations sent to the board and therefore was not investigated by the law firm.

Antoine Gosset-Grainville, who led the probe for law firm BDGS, concluded the allegations were without merit.

“Accor Group confirms that, in compliance with the principles of the highest standards of corporate governance, it has conducted an independent investigation following anonymous allegations involving its leader. The findings of this thorough investigation confirmed that there were no breaches of the legal or fiduciary obligations incumbent upon him,” the company said.

Accor’s board “unanimously endorsed these findings” and closed the investigation. “The Group reserves the right to assert its legal rights in order to put an end to these baseless allegations,” it added. BDGS declined to comment.

The allegations investigated by Gosset-Grainville, who also serves as the chair of Axa, included whether there had been irregularities or favouritism in the appointment in 2025 of one of the company’s external communications advisers into a senior executive role at Accor.

The woman was recruited into a position at Accor’s luxury hospitality division Ennismore, which is pursuing a stock market listing that could generate a significant windfall for its executives.

Accor is preparing to recruit a successor to Bazin, who announced in May that he would step down by the time his term expires in May 2028. Bazin, the former chair of football club Paris Saint-Germain, has been chief executive and chair of Accor since 2013.

BDGS also investigated whether Bazin’s close relationship with de Gourcuff influenced Accor’s dealings with his hospitality company Paris Society.

Accor acquired Paris Society in 2022 after making an initial investment in 2017. The hotel group last year sold back about 20 of Paris Society’s nightclubs to de Gourcuff, who had continued to manage the business under Accor’s ownership. The terms of the deals were never disclosed.

The board was urged to examine why the transaction was reversed so quickly and if there were adequate safeguards in place to ensure the interests of Accor shareholders were protected.

The transactions were approved by Accor’s investment committee and the decision to sell the nightclubs was consistent with the company’s strategy of disposing of so-called nightlife assets, according to a person familiar with the matter.

Paris Society said Bazin and de Gourcuff only met in 2017 and their relationship was “primarily professional”. They added that given nightclubs were “never a strategic focus” for Accor it was “quite natural” for them to be sold.

“This transaction has undergone all the necessary approval processes . . . it creates value for shareholders. Therefore, it has nothing to do with any kind of preferential treatment or a sudden change of course,” Paris Society added.

The probe has come at a turbulent time for Accor. The Paris-listed hotel group, which operates more than 5,000 hotels and 45 brands worldwide, was this year targeted by short seller Grizzly Research, which alleged the company failed to adequately safeguard against potential human trafficking and child sex exploitation.

Accor’s chief sustainability officer Coline Pont said in May that an independent investigation had confirmed that the company had “no systemic deficiencies” in its procedures.

The intense scrutiny in recent months has prompted questions internally over whether there is a concerted effort to destabilise the company.

Accor’s portfolio ranges from the budget chain Ibis to luxury hotel brand Raffles and the Orient Express. Bazin has turned the group into an asset-light operator of hotel franchises and expanded the previously Europe-centric group further into Asia and the Middle East.

Accor’s shares have, however, lagged the wider market, with critics arguing that acquisitions made by Bazin have made Accor overly complex.

The group has been targeted by activist investor Parvus Asset Management, which has amassed a 15 per cent stake. In a filing last year, Parvus said it did not intend to take control of Accor or seek a board seat, but that it would be “particularly attentive to Accor’s governance”.

FT : Trump envoy’s tour on $450mn superyacht stirs anger in Italy Rome declines

Trump envoy’s tour on $450mn superyacht stirs anger in Italy
Rome declines to reveal cost of security for billionaire businessman Tilman Fertitta’s ‘coastal diplomacy’

Donald Trump’s ambassador to Italy, Texas-based billionaire businessman Tilman Fertitta, has triggered controversy with a two-month diplomatic outreach tour of Italian seaside towns on his private $450mn superyacht.

In celebration of the 250th independence anniversary of the US and to reaffirm US-Italy ties, Fertitta’s 117-metre vessel is cruising to 13 of Italy’s best-known coastal cities — including Palermo and northern ports such as Venice, Genoa and Trieste.

Along the way, Fertitta — whose entertainment and hospitality empire includes the Houston Rockets basketball team, the Golden Nugget casino business and Landry’s restaurants — is inviting politicians, business leaders and military personnel to visit him on the luxurious vessel Boardwalk, which has a swimming pool, mini-golf course and helipads.

Before the “coastal diplomacy” cruise got under way last month, the US embassy in Rome said Fertitta — whose grandparents emigrated to the US from the Sicilian town of Cefalù, which he also visited — “will personally fund the Boardwalk’s trip”.

The statement said the trip would allow Fertitta, whose net worth is estimated by Forbes at nearly $11bn, to “connect personally with Italian people along Italy’s coastline”. It comes as many Italians are reeling from Trump’s verbal attacks on Prime Minister Giorgia Meloni, once one of his most stalwart allies.

But there has been an outcry over the huge security operation — including a special sea surveillance mission, involving boats and helicopters from the Italian coastguard, financial police and port authorities — required to protect the ambassador and his superyacht during their voyage. 

A lawmaker from the Green Left Alliance, Luana Zanella, raised the issue in parliament on Friday morning, slamming Fertitta’s tour on his “gigantic, ultra-luxurious” yacht as little more than a “diplomatic vacation” at the cost of the cash-strapped Italian state. “This display of opulence is not right,” Zanella, who comes from Venice, said.

Valentino Valentini, vice-minister of business and industry, gave no estimate of the cost of the security operation, but said Rome was obliged under the Vienna Convention to ensure the safety, freedom and dignity of all foreign ambassadors to Italy, including with “the provision of a special guard” if necessary.

He said Fertitta had been deemed a high-risk target, entitled to “first-level exceptional protection” at all times. The Boardwalk, he said, was also entitled to protection as it was serving as Fertitta’s temporary residence, means of transport and venue for institutional meetings.

Fertitta and the US embassy in Rome have not commented publicly on the criticisms, and the US state department did not immediately respond to a request for comment.

The Boardwalk arrives in Venice on Friday, where Fertitta is expected to face angry protests from a group of locals.

‘‘It’s a very weird way to do diplomacy,” said researcher and activist Stella Faye, who is helping to organise the protests. “It’s very emblematic of the political model that Trump is trying to build joining political and economic power.”

Fertitta’s visit coincides with the city’s annual Redentore festival, which celebrates the end of a devastating plague in 1576. The Boardwalk is set to be docked along what is normally a prime public viewing spot for fireworks.

But an Italian foreign ministry official said the superyacht tour had become a cruise of “friendship and fun”, helping to reaffirm the ambassador’s personal goodwill towards Italy, after a turbulent period in the bilateral relationship.

Antonio Tajani, the foreign minister, told the FT that Fertitta was playing an important role as an interlocutor between Meloni’s government and the Trump administration, and responding to Rome’s concerns in an “active, sensitive and above all, consistently positive manner”.

>>> La Lettre - Abivax

## Version française

**L'Événement — Santé**

**La biotech Abivax réactive sa banque d'affaires Centerview pour discuter avec les Big Pharma**

Le groupe de Marc de Garidel avait suspendu fin juin les discussions avec des groupes pharmaceutiques anglo-saxons comme AstraZeneca et Eli Lilly, le temps de mener sa levée de fonds de quelque 800 millions d'euros. Ses nouvelles capacités de financement lui permettent d'aborder les négociations en vue d'un éventuel rachat sans urgence ni pression.

Abivax reprend discrètement le chemin des discussions avec quelques-uns des grands laboratoires anglo-saxons en vue d'un potentiel rachat. D'après les informations de *La Lettre*, la biotech spécialisée dans le traitement de maladies inflammatoires chroniques a relancé la semaine dernière sa banque d'affaires, l'américain Centerview Partners, afin qu'elle poursuive les tractations. Ces négociations, entamées à la suite de premières marques d'intérêt l'an dernier, ont connu des rebondissements avant qu'Abivax ne procède finalement à une levée de fonds de quelque 800 millions d'euros tout début juillet (LL du 11/06/26).

Compte tenu de ses 10 milliards d'euros de valorisation boursière, après avoir vu son cours de Bourse flamber de 1 500 % sur un an, le groupe français dirigé par Marc de Garidel est devenu une cible d'acquisition chère. Peu de grands laboratoires ont les ressources financières suffisantes pour se lancer à l'assaut d'Abivax, coté à Paris et à New York.

**Des résultats cliniques bien accueillis**

Des poids lourds comme le britannique AstraZeneca et l'américain Eli Lilly sont toujours intéressés par le rachat d'Abivax (LL du 12/01/26 et 20/01/26). L'attention qu'ils portent à la biotech remonte déjà à l'été 2025, quand avaient été annoncés les résultats d'essais cliniques particulièrement prometteurs de son candidat médicament contre la rectocolite hémorragique, l'obefazimod.

Le laboratoire américain Merck & Co avait aussi manifesté son intérêt, mais il ne convoiterait pas le traitement de la maladie de Crohn, cette maladie inflammatoire du tube digestif, que développe aussi Abivax. D'où l'idée de Merck de s'allier à un autre laboratoire.

L'appétit des grands groupes pharmaceutiques s'est récemment réaffirmé avec la publication des données finales des essais cliniques de l'obefazimod, dits de phase III. Ces résultats ont confirmé la sécurité du candidat médicament, dont la commercialisation aux États-Unis est toujours prévue pour 2027, dès que la Food and Drug Administration (FDA), l'autorité sanitaire américaine, aura donné son feu vert.

Pour dissiper les doutes sur le potentiel du futur traitement, après la révélation de trois cas de cancer au cours des essais cliniques, Marc de Garidel avait même avancé le calendrier de la publication des essais, l'annonçant à fin juin au lieu de mi-juillet comme initialement prévu. L'ancien PDG du groupe pharmaceutique Ipsen avait aussi enchaîné les conférences téléphoniques avec les analystes pour rassurer le marché, après avoir vu l'action Abivax chuter de 40 % (LL du 11/06/26).

**Visibilité financière jusqu'en 2029**

Le patron d'Abivax s'est aussi fixé pour ligne de mener les discussions avec l'acquéreur potentiel sans pression ni précipitation. Grâce aux 800 millions levés tout début juillet, Marc de Garidel a doté son groupe d'une visibilité sur le financement de ses activités, notamment dans la recherche, jusqu'à fin 2029.

Dans une interview à la chaîne américaine CNBC le 10 juillet, cet ingénieur de formation s'est même dit en capacité de lancer une commercialisation autonome de l'obefazimod, c'est-à-dire sans avoir besoin d'adosser Abivax à un gros laboratoire. *« La meilleure défense pour nous, c'est en réalité l'attaque »*, a alors affirmé le dirigeant en réponse à une question sur une possible prise de contrôle de son groupe. Sur cette même chaîne, il avait déjà affiché en mars sa confiance dans la possibilité de négocier un deal aux meilleures conditions une fois les données de phase III publiées.

*Matthieu Protard*

>>> Europe : Brokers Upgrades & Downgrades - 17th of July 2026 V2(+)

>>> Up
* 3M Co Raised to Overweight at JPMorgan; PT $180
* ABB Raised to Buy at Pareto Securities; PT 96.40 Swiss francs
* Adecco Raised to Outperform at BNP Paribas; PT 24 Swiss francs
* Adecco ADRs Raised to Outperform at BNP Paribas; PT $15.30
* Apple Raised to Buy at HSBC; PT $366
* ASML Raised to Buy at DZ Bank; PT 1,800 euros (+)
* Atea Raised to Buy at Danske Bank Markets; PT 180 kroner (+)
* Atlas Copco Raised to Buy at SB1 Markets; PT 225 kronor
* BMW Raised to Buy at HSBC on Neue Klasse, ‘Realistic’ Guidance
* Eltel Raised to Accumulate at Inderes; PT 14 kronor
* Emerson Electric Raised to Overweight at JPMorgan; PT $157
* Fiskars Raised to Reduce at Inderes; PT 11.50 euros
* HMS Networks Raised to Buy at Handelsbanken; PT 580 kronor
* IntegraFin Raised to Buy at Jefferies; PT 440 pence
* Johnson & Johnson Raised to Buy at Freedom Capital; PT $280
* NatWest Raised to Outperform at KBW; PT 735 pence
* Scanfil Raised to Accumulate at Inderes; PT 12.50 euros
* Sodexo Raised to Reduce at AlphaValue/Baader
* Tele2 Raised to Buy at Danske Bank Markets; PT 187 kronor (+)
* Telenor Raised to Buy at Pareto Securities; PT 150 kroner
* Telenor Raised to Buy at Danske Bank Markets; PT 157 kroner (+)
* Trelleborg Raised to Hold at ABG; PT 415 kronor
* Tritax Big Box Raised to Buy at Van Lanschot Kempen (+)
* Verkkokauppa.com Raised to Buy at Nordea; PT 4 euros
* Xilam Animation Raised to Accumulate at Euroland Corporate (+)

>>> Down
* Crest Nicholson PT Cut to 70 pence from 78 pence at Berenberg
* Datalogic Cut to Reduce at Equita; PT 5.70 euros (+)
* Delivery Hero Cut to Neutral at UBS; PT 41.50 euros
* Lem Cut to Hold at Research Partners; PT 382 Swiss francs (+)
* Lloyds Cut to Market Perform at KBW; PT 120 pence
* Nordea Bank Cut to Reduce at Inderes; PT 17.50 euros
* Rotork Cut to Hold at Berenberg; PT 503 pence
* Smaio Cut to Accumulate at Euroland Corporate; PT 8.70 euros (+)

>>> Initiation
* Zehnder Rated New Outperform at Oddo BHF; PT 84 Swiss francs

>>> Call
* Adecco Receives Upgrade From BNP Paribas: Europe Research Digest (+)
* IntegraFin Set to Be a Winner in ‘Shake-Out,’ Jefferies Upgrades
* Sobi Offers Further Upside, PT to Street-High at Berenberg

FT : The mega-IPO glut comes with a containment problem Never let your left hand

The mega-IPO glut comes with a containment problem
Never let your left hand know what your right hand is doing

It could be considered the absolute definition of a champagne problem. Goldman Sachs and Morgan Stanley’s tech investment banking teams are so dominant that they won joint lead status on all three of the big “hyperscaler” IPO deals of 2026: SpaceX, Anthropic and OpenAI.

That is really quite a triumph, because usually companies are a bit reluctant to retain the same firm that’s advising on a similar deal in the same timeframe for one of their biggest competitors. And with the fees on SpaceX likely to have been into nine figures, and similar to come, it’s very economically material to all involved.

But, problems there are. Because the reason that companies are so reluctant to share advisers with their competitors is that they are, understandably, worried about information leakage and conflicts of interest. And because the bankers are worried about getting sued, as occasionally happens, they erect great big information-proof Chinese walls internally, to make sure that nobody slips up.

Goldman Sachs and Morgan Stanley have had to create entirely separate deal teams, with no overlap of personnel between OpenAI and Anthropic, and not even any contribution from bankers who previously worked on SpaceX (where the conflict could come from any secondary sales planned once the lock-ups expire).

This shouldn’t really matter in booming markets. As long as the investor demand for anything tech-flavoured is limitless, then there’s nothing to be gained from the teams talking to one another. Their only real job is to execute the transaction and fend off the disappointed phone calls from people who didn’t get as many shares allocated as they wanted.

So as long as everything’s going completely brilliantly, there’s no need to worry about anything at all..


Aha.
Oooer.

Of course, Alphaville is aware that the greatest of all fallacies is to reason from a price change. But if we were to consider that one possible reason for the rapid re-entry from orbit of both the equity and bonds of SpaceX might be that investor demand for tech megacaps wasn’t limitless, that might cause some problems. Because it would mean that the finite demand had to be allocated across three different sources of supply — Anthropic, OpenAI and SpaceX secondary sales.

Normally that’s not such a big deal, because the way in which it gets sorted out is through open market competition — if the deals all had different advisers, then it would simply be a case of “may the best team win”. Whoever was best at persuading investors (and whichever issuer had the best underlying story) would get their deal away and take the bragging rights, while the losers would be left weeping into their beer.

But it’s much more difficult for that to happen in this situation. Because although GS and MS split their capital markets advisory teams up to prevent information leakage, they didn’t also decide to set up entirely separate equity sales forces and research departments. So despite the carefully maintained Chinese walls stopping information from one deal leaking to the advisers on another, the only piece of information that anyone actually needs to know right now — the amount of investor interest in the three different transactions — is coming from the exact same source.

Which creates something of a compliance minefield for the poor old infantry on the dealing floors. To avoid creating a conflict of interest, they need to treat all three internal teams with scrupulous fairness, making sure that everyone gets perfectly unbiased feedback on their own transactions, not giving any of the bankers a clue about what they might be saying to other teams and doing their best to avoid giving any impression to buy-side clients that they might be pushing one deal a little harder than the other.

It is no aspersion whatsoever on the fine men and women of the equity sales industry to say that this will place quite extraordinary demands on their tact and professionalism. Alphaville is confident that Morgan Stanley and Goldman Sachs bankers and traders are up to the task — but it might be a good idea to delete WhatsApp from their phones for a while, to minimise the temptation to have the kind of friendly coffee catch-up that looks so much worse when it’s being discussed under subpoena.

>>> Europe : Brokers Upgrades & Downgrades - 17th of July 2026

>>> Up
* 3M Co Raised to Overweight at JPMorgan; PT $180
* ABB Raised to Buy at Pareto Securities; PT 96.40 Swiss francs
* Adecco Raised to Outperform at BNP Paribas; PT 24 Swiss francs
* Adecco ADRs Raised to Outperform at BNP Paribas; PT $15.30
* Apple Raised to Buy at HSBC; PT $366
* Atlas Copco Raised to Buy at SB1 Markets; PT 225 kronor
* BMW Raised to Buy at HSBC on Neue Klasse, ‘Realistic’ Guidance
* Eltel Raised to Accumulate at Inderes; PT 14 kronor
* Emerson Electric Raised to Overweight at JPMorgan; PT $157
* Fiskars Raised to Reduce at Inderes; PT 11.50 euros
* HMS Networks Raised to Buy at Handelsbanken; PT 580 kronor
* IntegraFin Raised to Buy at Jefferies; PT 440 pence
* Johnson & Johnson Raised to Buy at Freedom Capital; PT $280
* NatWest Raised to Outperform at KBW; PT 735 pence
* Scanfil Raised to Accumulate at Inderes; PT 12.50 euros
* Sodexo Raised to Reduce at AlphaValue/Baader
* Telenor Raised to Buy at Pareto Securities; PT 150 kroner
* Trelleborg Raised to Hold at ABG; PT 415 kronor
* Verkkokauppa.com Raised to Buy at Nordea; PT 4 euros

>>> Down
* Crest Nicholson PT Cut to 70 pence from 78 pence at Berenberg
* Delivery Hero Cut to Neutral at UBS; PT 41.50 euros
* Lloyds Cut to Market Perform at KBW; PT 120 pence
* Nordea Bank Cut to Reduce at Inderes; PT 17.50 euros
* Rotork Cut to Hold at Berenberg; PT 503 pence

>>> Initiation
* Zehnder Rated New Outperform at Oddo BHF; PT 84 Swiss francs

>>> Call
* IntegraFin Set to Be a Winner in ‘Shake-Out,’ Jefferies Upgrades
* Sobi Offers Further Upside, PT to Street-High at Berenberg

>>> What to look at today - 17th of July 2026

Asian stocks fell alongside US equity-index futures as a selloff in chipmakers deepened with investors questioning whether they had rallied too far and too fast earlier this year. Oil climbed. MSCI’s Asia Pacific equities gauge dropped 2.1%, with Japan’s Nikkei 225 Stock Average losing 4.4%. Taiwan Semiconductor Manufacturing Co. dropped more than 4% as the chip bellwether’s solid earnings outlook was overshadowed by a higher spending forecast. Kioxia Holdings Corp. sank by 15% in Tokyo, halving its market capitalization in just a month. Netflix Inc. also weighed on sentiment, with shares falling 9% in extended trading after the company forecast a second straight quarter of slowing sales growth. Equity-index futures for the Nasdaq 100 Index retreated almost 1%.  Elsewhere, Brent rebounded from Thursday’s losses as hostilities across the Middle East continued to escalate and shipping traffic slumped in the Strait of Hormuz. The commodity traded just below $85 a barrel and was up 12% for the week, on track for its biggest weekly gain since April and rekindling inflation concerns. Technology stocks have come under pressure in recent weeks as investors increasingly question whether this year’s blistering AI-driven rally has run too far, too fast. While softer US inflation has eased expectations of an immediate Federal Reserve interest-rate hike and Middle East tensions continue to drive oil prices, the focus remains on AI earnings for evidence that billions of dollars in spending will translate into returns. In other corners of the market, Government bonds edged lower in Australia and Japan. Treasuries were little changed, with the yield on the benchmark 10-year holding at 4.55%. The yen traded around 162.45 per dollar even as Japan’s Finance Minister Satsuki Katayama renewed her warning of possible intervention in the market as the currency continued to hover near its lowest level in four decades. Gold was on track for its biggest weekly loss since early June as renewed hostilities in the Middle East and rising oil prices fueled speculation the Federal Reserve may keep interest rates higher for longer. The dollar was a touch stronger against most of its major peers. That was due to a combination of the selloff in technology stocks, rising energy prices, and higher US real yields, said Chidu Narayanan, chief Asia Pacific strategist at Wells Fargo in Singapore. Attention remained firmly on the semiconductor sector as investors questioned whether tech stocks had become too richly valued. Alphabet Inc. sank 4.4% Thursday after Google was said to be months behind schedule in delivering its flagship AI model. Traders are grappling with whether the more than $725 billion the four biggest US AI operators are expected to spend this year will translate into returns. The Philadelphia Semiconductor Index has dropped about 19% from a June peak. A gauge of Asian semiconductor makers was headed for its biggest weekly decline since early March, with Japanese companies taking a hit on Friday and South Korean markets closed. US After Hours NFLX -8.2% lower on earnings; ISRG -11%, STAA -8.5%, FFIN -3.4%, AA -2.9% also lower on earnings/guidance.

Nikkei -5,38% Hang Seng -2,52% CSI -3,97% Kospi -6.37% Shanghai -3,12% Shenzen -3.15%

Eur$ 1.1438 CNH 6.7767 CNY 6.7751 JPY 162.40 GBP 1.3465 CHF 0.8089 RUB 78.1000 TRY 47.1627 WTI$ 79.84 +1.13% Gold 3,989 -0.07% BTC 63,455 -0.96% ETH 1,849 -1.12%

S&P -0.90% Nasdaq -1.55% EuroStoxx -0.87% FTSE -0,48% Dax -0.66% SMI -0,20%

Macro :
- Burnham to Back North Sea Oil, Take Control of Thames Water
- Fed’s Jefferson Says Policy Well Positioned If Inflation Cools
- Coatue Leads Databricks Funding Round at $188 Billion Valuation
- *STOXX EUROPE 600 SEEN AT 647 AT END-2026, BLOOMBERG POLL SHOWS

Keep an eye on :
- ADKO AV : Brandes Investment Partners Supports NLB Offer for Addiko Shares
- ADP FP : Groupe ADP June Passenger Traffic -1.4%
- AIR FP : Boeing, Airbus Vie for Major Plane Order From Jet Lessor SMBC
- AMUN FP : Amundi Says SBI Funds Management IPO Price Set at Top of Range
- BEIAB SS : Beijer Alma Reports 2Q Revenue of SEK 2.13 Billion, Compared With FactSet Estimates of SEK 2.13 Billion
- BETSB SS : Betsson 2Q Operating Profit Beats Estimates
- CS FP : AXA Sells Its Ardian Stake as ACM, Wafra Expand Their Ownership
- BHG SS : BHG Group 2Q Sales Beat Estimates
- CTEK SS : CTEK 2Q Sales Miss Estimates
- COTN SW : Comet Disappointed With US Court Decision of New XP Power Trial
- CVC NA : CVC DIF to Sign Deal to Buy Ecoeridania, Sole Reports
- 699925 CH : CMXT : CXMT’s mega IPO draws frenzy from retail investors to DeepSeek founder’s fund
- DANSKE DC : Danske Bank Boosts FY Net Income Forecast (1)
- DSY FP : Dassault Systèmes in Talks to Buy ArisGlobal for About $2b: FT
- DBV FP : DBV Tech 1H Net Loss $98.0M
- EQT SS : EQT 1H Adjusted Ebitda Beats Estimates
- ESSITYA SS : Activist Investor Cevian Acquires 5.6% Stake in Essity
- EVO SS : Evolution 2Q Ebitda Misses Estimates
- GF SW : Georg Fischer 1H Ebit Loss CHF33M, Est. Profit CHF80.6M
- GOOGL US : Alphabet Sinks on Gemini Delay Report, Struggles At 50-Day
- INSTAL SS : Instalco 2Q Sales Beat Estimates
- KEMIRA FH : Kemira Maintains FY Revenue Forecast
- LAGRB SS : Lagercrantz 1Q Net Revenue Beats Estimates
- LINDEX FH : Lindex 2Q Net Sales EU259.5M
- ISP IM : Paschi Casts Doubts Over Intesa Bid, Suggests Studying BPM Plan
- BMPS IM : Banco BPM Welcomes Paschi Board Statement on Tie-up Proposal
- MTRS SS : Munters 2Q Net Sales Miss Estimates
- NOVN SW : Novartis Kidney Drug Fabhalta Gets FDA Traditional Approval
- ORIOLA FH : Oriola 2Q Net Sales Miss Estimates
- PSKY US : Paramount Judge Skeptical of Consumer Suit Over Warner Bros Deal
- RATOB SS : Ratos 2Q Oper Profit From Cont Ops SEK1.35B Vs. SEK834M Y/y
- RIEN SW : Rieter 1H Net Loss CHF54.9M Vs. Loss CHF20.0M Y/y
- SAABB SS : Saab 2Q Operating Profit Beats Estimates
- SCST SS : Scandi Standard 2Q Operating Income Beats Estimates
- SKAB SS : Skanska 2Q Operating Profit Beats Estimates
- S92 GY : SMA Solar Sees FY Sales EU1.63B to EU1.73B
- SKFB SS : SKF 2Q Adjusted Operating Profit Beats Estimates
- SPCX US : SpaceX Scrubs Launch of Starship Rocket After Engine Failure
- TELIA SS : Telia 2Q Adjusted Ebitda Meets Estimates
- TOM NO : Tomra 2Q Revenue EU405M
- TTE FP : Slim’s Carso Buys Stake in Mexican Oil Field From TotalEnergies
- TRUEB SS : Truecaller 2Q Revenue Beats Estimates
- VEND NO : Vend Marketplaces 2Q Ebitda Misses Estimates
- VPLAYB SS : Viaplay 2Q Sales SEK5.51B
- VIMIAN SS : Vimian 2Q Revenue Beats Estimates
- VOD LN : Niel’s Vega to Buy Additional 2.74% of Vodafone Shares
- VOLCARB SS : Volvo Car CEO Says China Downturn Came Faster Than Expected
- VOW GY : German State Backs Israel Defense Co Ops on Volkswagen Site:Rtrs

>>> Stoxx 600 Pre-Market Indications

  • Telenor (TEQ TH) +2%
    • Telenor Raised to Buy at Pareto Securities; PT 150 kroner
  • Abivax (2X1 TH) +1.1%
  • Sandoz Group (D8Y TH) +0.8%
  • Danske Bank (DSN TH) +0.8%
    • *DANSKE BANK SEES FY NET DKK23B TO DKK25B, SAW DKK22B TO DKK24B
  • BMW (BMW TH) +0.1%
    • BMW Raised to Buy at HSBC on Neue Klasse, ‘Realistic’ Guidance
  • Hochtief (HOT TH) -2.4%
  • Nordex (NDX1 TH) -2.5%
  • Siemens Energy (ENR TH) -2.9%
  • Infineon (IFX TH) -3.9%
  • BE Semiconductor (BSI TH) -4.6%
  • Aixtron (AIXA TH) -4.6%
  • AT&S (AUS TH) -4.8%
  • STMicro (SGM TH) -5.1%
    • Infineon, STMicro’s AI Power Gains Set to Extend Beyond Kyber
  • ASM Intl (AVS TH) -5.2%
  • Nokia (NOA3 TH) -5.4%

>>> TradeGate Pre-Market Indications

DAX:
  • BMW (BMW TH) +0.3%
    • BMW Raised to Buy at HSBC on Neue Klasse, ‘Realistic’ Guidance
  • Deutsche Bank (DBK TH) -1.3%
  • Zalando (ZAL TH) -1.3%
  • Siemens (SIE TH) -1.4%
  • Siemens Energy (ENR TH) -2.2%
  • Infineon (IFX TH) -3.4%
MDAX:
  • Nordex (NDX1 TH) -2.5%
  • Jenoptik (JEN TH) -3.5%
  • Siltronic (WAF TH) -3.9%
  • Aixtron (AIXA TH) -4.4%
  • SUSS MicroTec (SMHN TH) -4.9%
SDAX:
  • SMA Solar (S92 TH) +9.9%
    • SMA Solar Having ‘Terrific’ First Half, Lifts Outlook: Jefferies
  • Heidelberger Druck (HDD TH) -1%
  • PVA TePla (TPE TH) -1.3%
  • Deutsche PBB (PBB TH) -2.1%
  • LPKF (LPK TH) -4.7%
  • Dermapharm (DMP TH) -5.5%
    • Financial regulator BaFin investigates Dermapharm’s annual financial statements: APA